GHK-Cu (copper peptide): what the research actually says

GHK-Cu (glycyl-histidyl-lysine bound to copper) is unusual on this site because it is genuinely two different products wearing one name: a topical skincare ingredient with decades of supporting research, and an injectable "wellness" peptide with almost none. Conflating the two is where the misleading marketing happens — and understanding that split is the whole point of this page.

What GHK-Cu is and where it comes from

GHK-Cu is a small tripeptide that binds copper and occurs naturally in the human body, found in plasma, saliva, and urine. Natural plasma levels are approximately 200 ng/mL at age 20, declining to roughly 80 ng/mL by age 60 — a drop that has long been cited as part of the rationale for studying supplemental GHK-Cu in aging contexts. The peptide was first isolated from human plasma albumin by researcher Loren Pickart in 1973 and has been an active subject of biochemical research since the late 1980s, when it began attracting attention for wound healing.

It is called a "copper peptide" because the tripeptide GHK has a strong affinity for copper(II) ions, forming the GHK-Cu complex. To understand what GHK-Cu actually is and how it relates to other peptides under study, see our overview of what peptides are.

The biology: what GHK-Cu does in the body

GHK-Cu has been studied for a wide range of biological activities, primarily in cell culture and animal models. The evidence base shows it stimulates collagen and elastin synthesis in skin fibroblasts, promotes the production of glycosaminoglycans, and modulates the activity of enzymes involved in tissue remodeling (matrix metalloproteinases and their inhibitors). It also attracts immune and endothelial cells to wound sites and stimulates growth factors including brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF).

A 2015 review in BioMed Research International summarized the gene-level picture: GHK-Cu appears capable of modulating a very large number of human genes across multiple pathways involved in tissue repair, antioxidant defense, and inflammation control.⁵ That breadth of activity at the molecular level is part of why the research field remains active — and part of why the marketing around injectable versions often extrapolates far beyond what the human evidence actually supports.

Copper itself is an essential mineral for biological processes including collagen formation (via lysyl oxidase), antioxidant defense (via superoxide dismutase), and cellular respiration. GHK-Cu's ability to deliver non-toxic copper into cells — its redox activity is silenced when copper is complexed with the tripeptide — is considered a key part of its biological mechanism.

The topical evidence: the stronger of the two cases

Topical GHK-Cu is an active area of published research with a meaningful body of animal and some human cosmetic data. In animal wound healing studies, the effects have been notably consistent. In one controlled study of ischemic open wounds in rats, wound area had decreased by 64.5% in the GHK-Cu–treated group after 13 days, compared with 45.6% in a vehicle-treated group and 28.2% in untreated controls — a statistically significant difference accompanied by lower concentrations of the inflammatory marker TNF-alpha.⁶ Similar wound-healing effects have been reproduced across rabbits, mice, and pigs.

For topical skincare specifically, a 2025 review in Molecules examined the challenge of delivering GHK-Cu through the skin's lipophilic stratum corneum, noting that liposome encapsulation may improve its permeation potential.² Several controlled facial studies have found anti-aging, firming, and anti-wrinkle activity from topical copper peptide formulations, though with relatively small sample sizes and short durations.

Harvard Health Publishing notes that "some evidence suggests that some peptides in eye creams that stimulate collagen could possibly help skin appear more youthful" — a cautious but real statement of supporting evidence, not an endorsement. That characterization is accurate for what the literature shows.

Because topical GHK-Cu is applied as a cosmetic ingredient rather than injected, it falls under a different regulatory bar: the FDA regulates cosmetics but does not approve them before they reach the market the way it approves drugs. That is a meaningfully lower bar than a regulated medication clears, but it also means topical GHK-Cu skincare products are not operating in the same unregulated void as injectable wellness peptides.

The injectable version: a different, much weaker case

Injectable or subcutaneous GHK-Cu, marketed for broader anti-aging, hair, or general wellness claims, is a separate product with a separate evidence problem. It is not an FDA-approved drug. Controlled human trials examining injectable GHK-Cu at the doses and formulations sold by wellness clinics essentially do not exist in the published literature. The 2026 research that does exist focuses on novel formulations for wound treatment — such as a GHK-Cu–loaded hydrogel system studied for diabetic wound healing in laboratory settings — rather than on the commercial injectable products currently on the market.³

Injectable GHK-Cu is typically sold through the same "research use only" channel as other unapproved peptides. Injecting anything introduces sterility, dosing, and systemic-absorption risks that a topical cream never has to answer for, which makes the evidence gap here matter more, not less. The American Medical Association has noted that with newer injectable peptides, physicians face a situation where "we don't have data from trials" and "there's minimal evidence on the side effects or consequences of long-term or frequent dosing."⁴

Evidence-grade table

The following grades reflect the strength of the published evidence for specific uses of GHK-Cu. Grading follows a simplified A–D framework (A = strong RCT evidence; B = consistent animal/small human data; C = in vitro or limited data; D = theoretical/absent).

Route comparison: two products, one name

"When you're talking about peptides being promoted online, those health claims have not been vetted by any expert group, the FDA, or anyone else. The health claims are divorced from data."

— Dr. Pieter Cohen, Associate Professor of Medicine, Harvard Medical School, in Harvard Health Publishing (July 2026)

What the clinical trial picture actually shows

For injectable peptides broadly, physicians have been clear about the limits of the existing data. Dr. Anthony Tam, a family and sports medicine physician with Henry Ford Health and team physician for USA Wrestling and USA Cycling, speaking to the American Medical Association, noted that for newer injectable peptides like GHK-Cu: "there was one human trial study involving about 10 to 12 people for knee pain recovery. The details were limited, but the results suggested there may be some promise." He added: "unfortunately, there just isn't enough valuable, statistically significant evidence that points us to be able to recommend them safely."⁴

That gap — animal and in vitro data that looks promising, no adequate human trials — is the defining feature of injectable GHK-Cu's evidence status as of 2026. It does not mean the peptide has no effects in humans. It means we genuinely do not know what it does at the doses and formulations being injected, because the controlled trials to answer that question have not been done.

What's known about safety

Topical GHK-Cu products are widely used cosmetic ingredients with a multi-decade track record on skin. That safety history applies specifically to topical use. Injectable GHK-Cu carries the same open questions as other unapproved injectable peptides: no established human dosing, no long-term safety data, and no guaranteed verification of what's actually in a "research use only" vial. The FDA has flagged that gray-market injectable peptides "may be contaminated with impurities" because they are often manufactured without oversight, sometimes overseas. See our full safety overview and our legal status guide for broader context on this class of products.

The injectable version also raises a question the topical version never has to answer: systemic exposure. When GHK-Cu is applied to skin, its permeation through the stratum corneum is limited by its hydrophilic nature — a feature, not a flaw, from a safety standpoint. Injecting a compound bypasses that barrier entirely, meaning any systemic effects (positive or negative) are far more direct and harder to predict from topical data.

The regulatory gap, explained

The route to market for injectable GHK-Cu sold at wellness clinics or through online "research use only" vendors has no FDA-approved pathway. These products are not compounded medications under a valid prescription for a specific patient (which has its own regulatory requirements), nor are they approved new drugs. They occupy a gray area that the FDA has periodically moved to close — banning specific peptides from compounding or issuing warning letters — but enforcement is uneven and the market continues to operate. Understanding where a specific product sits in this landscape matters before trusting any claim made about it.

If you're considering GHK-Cu

For skin goals, a dermatologist can advise on evidence-backed topical options — GHK-Cu is a legitimate cosmetic ingredient with real research, and some formulations are available through mainstream skincare. For anything injectable, the same rule applies as elsewhere on this site: a licensed clinician, not a research-chemical vendor, is the only channel with any quality control. Our guide to trying peptides safely walks through how to find a legitimate provider and what questions to ask before agreeing to any injection.